Bone-metastatic prostate cancer is common in men with recurrent castrate-resistant disease.
To date, therapeutic focus has largely revolved around androgen deprivation therapy (ADT) …

Immune targeted therapy of nitric oxide (NO) synthases are being considered as a potential
frontline therapeutic to treat patients diagnosed with locally advanced and metastatic …

Docetaxel (DTX) is used against breast cancer despite its side effects such as toxicity and
immunosuppression. Here we investigated the cytotoxic and immunomodulatory effects of …

Adipocyte–tumor cell cross-talk is one of the critical mediators of tumor progression and an
emerging facilitator of therapy evasion. Tumor cells that metastasize to adipocyte-rich bone …

Colon cancer is a therapy-resistant cancer with a low 5-year survival frequency. The drug 5-
fluorouracil (5-FU) has been used as a first-line therapy in metastatic colon cancer in …

Cancer is the result of a cell's acquisition of a variety of biological capabilities or 'hallmarks'
as outlined by Hanahan and Weinberg. These include sustained proliferative signalling, the …

There is evidence that cancer stem-like cells (CSC) and neuroendocrine behavior play
critical roles in the pathogenesis and clinical course of metastatic castration-resistant …

Simple Summary Lipids (fatty substances) and cytokines are molecules that affect how the
immune response works. The measurement of the amounts of lipids and cytokines in blood …

The baseline value of neutrophil to lymphocyte ratio (NLR) has been found to be prognostic
in patients with metastatic castration resistant prostate cancer (CRPC). We evaluated the …

Poorly understood interactions with nonmalignant cells within the tumor microenvironment
play an important role in cancer progression. Here, we explored interactions between …